BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36063368)

  • 1. 5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
    Díaz-Santa J; Rodríguez-Romanos R; Coll R; Osca G; Pratcorona M; González-Bártulos M; Garrido A; Angona A; Talarn C; Tormo M; Arnan M; Vives S; Salamero O; Tuset E; Lloveras N; Díez I; Zamora L; Bargay J; Sampol A; Cruz D; Vila J; Sitges M; Garcia A; Vall-Llovera F; Esteve J; Sierra J; Gallardo D;
    Eur J Haematol; 2022 Dec; 109(6):755-764. PubMed ID: 36063368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
    Díaz-Santa J; Rodríguez-Romanos R; Osca G; Pratcorona M; Garrido A; Coll R; Moret C; Escoda L; Tormo M; Heras I; Arnan M; Vives S; Salamero O; Lloveras N; Bargay J; Sampol A; Cruz D; Garcia A; Quiñones T; Esteve J; Sierra J; Gallardo D;
    Leukemia; 2020 Nov; 34(11):2925-2933. PubMed ID: 32152464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.
    Hyo Kim L; Sub Cheong H; Koh Y; Ahn KS; Lee C; Kim HL; Doo Shin H; Yoon SS
    J Hum Genet; 2015 Dec; 60(12):749-54. PubMed ID: 26354033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
    Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
    J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
    Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
    Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
    J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.
    Jordheim LP; Nguyen-Dumont T; Thomas X; Dumontet C; Tavtigian SV
    Drug Metab Dispos; 2008 Dec; 36(12):2419-23. PubMed ID: 18775979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.
    Getz KD; Alonzo TA; Sung L; Meshinchi S; Gerbing RB; Raimondi S; Hirsch B; Loken M; Brodersen LE; Kahwash S; Choi J; Kolb EA; Gamis A; Aplenc R
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29313. PubMed ID: 34472213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
    Prebet T; Etienne A; Devillier R; Romeo E; Charbonnier A; D'incan E; Esterni B; Arnoulet C; Blaise D; Vey N
    Cancer; 2011 Mar; 117(5):974-81. PubMed ID: 20957721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
    Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M
    Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.
    Cheong HS; Koh Y; Ahn KS; Lee C; Shin HD; Yoon SS
    Pharmacogenet Genomics; 2014 Sep; 24(9):436-41. PubMed ID: 25000516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.